Skip to main
CVRX

CVRx (CVRX) Stock Forecast & Price Target

CVRx (CVRX) Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CVRx is well-positioned for long-term growth, highlighted by its strong 2026 revenue guidance of $63M-$67M and expanding utilization of its Barostim therapy. The company's commercial model is also showing signs of improvement, with consistent productivity and plans to expand its sales territories. CVRx's recently announced BENEFIT-HF trial, which is supported by CMS and has the potential to significantly expand its TAM, further adds to the positive outlook on the stock. Ultimately, with a strong pipeline and positive market developments, CVRx has the potential to drive significant value for investors in the long run.

Bears say

CVRx is showing signs of continued strong financial performance, with revenue and gross margins exceeding expectations and center growth in line with estimates. Additionally, recent developments, including the first enrollment in the BENEFIT-HF trial and the Category I CPT code implementation, could expand the company's indicated TAM and improve commercial access for its Barostim product. These factors, along with the company's ongoing engagement with payers, suggest a potential for sustained growth in the future, but potential investors should closely monitor the impact of the ongoing salesforce disruption and potential delays in reimbursement processes.

CVRx (CVRX) has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CVRx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CVRx (CVRX) Forecast

Analysts have given CVRx (CVRX) a Buy based on their latest research and market trends.

According to 2 analysts, CVRx (CVRX) has a Buy consensus rating as of Jul 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CVRx (CVRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.